Publikationen in Zusammenarbeit mit Forschern von Hospital Infantil Universitario Niño Jesus de Madrid (19)

2024

  1. Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment

    Biomedicine and Pharmacotherapy, Vol. 173

2023

  1. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  2. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  3. Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research

  4. Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity

    European Journal of Pediatrics, Vol. 182, Núm. 10, pp. 4633-4645

  5. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research, Vol. 194

2022

  1. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN

    Journal of Pediatric Gastroenterology and Nutrition, Vol. 75, Núm. 6, pp. 717-723

2021

  1. Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study (European Journal of Pediatrics, (2021), 180, 9, (3029-3038), 10.1007/s00431-021-04063-6)

    European Journal of Pediatrics

  2. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 2, pp. 447-457

  3. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study

    European Journal of Pediatrics, Vol. 180, Núm. 9, pp. 3029-3038

  4. Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease

    Pharmaceutics, Vol. 13, Núm. 1, pp. 1-17

2020

  1. Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease

    International Journal of Molecular Sciences, Vol. 21, Núm. 9

  2. Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease

    Journal of pediatric gastroenterology and nutrition, Vol. 71, Núm. 4, pp. 508-515

  3. Predictors of response to exclusive enteral nutrition in newly diagnosed crohn’s disease in children: PRESENCE Study from SEGHNP

    Nutrients, Vol. 12, Núm. 4

2015

  1. Commercial enteral formulas and nutritional support team

    Diet and Nutrition in Critical Care (Springer New York), pp. 1203-1219

2014

  1. The complete picture of changing pediatric inflammatory bowel disease incidence in Spain in 25years (1985-2009): The EXPERIENCE registry

    Journal of Crohn's and Colitis, Vol. 8, Núm. 8, pp. 763-769

2013

  1. Analysis of the Spanish national registry for pediatric home enteral nutrition (NEPAD): Implementation rates and observed trends during the past 8 years

    European Journal of Clinical Nutrition, Vol. 67, Núm. 4, pp. 318-323

2011

  1. Consensus on paediatric enteral nutrition access: A document approved by SENPE/SEGHNP/ANECIPN/SECP

    Nutricion Hospitalaria, Vol. 26, Núm. 1, pp. 1-15

2010

  1. Home parenteral nutritrion in children: Procedures, experiences and reflections

    Nutricion Hospitalaria, Vol. 25, Núm. 5, pp. 705-711